S234: UPDATED CLINICAL RESULTS OF FIRST-IN-HUMAN STUDY OF CD19/BCMA DUAL-TARGETING FAST CAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA

• Xinfeng Chen,
• Yu Ping,
• Ling LI,
• Lei Zhang,
• Xudong Zhang,
• Jianmin Huang,
• Jia Liu,
• Gui LI,
• Jiaping He,
• Hua Zhang,
• Wei Zhao,
• Lihong Weng,
• Wenjie Yin,
• Lianjun Shen,
• Wei William Cao,
• Wenling LI,
• Mingzhi Zhang,
• Yi Zhang

Affiliations

Xinfeng Chen

1 The First Affiliated Hospital of Zhengzhou University, Biotherapy Center, Zhengzhou, China

Yu Ping

1 The First Affiliated Hospital of Zhengzhou University, Biotherapy Center, Zhengzhou, China

Ling LI

2 The First Affiliated Hospital of Zhengzhou University, Cancer Center, Zhengzhou, China

Lei Zhang

2 The First Affiliated Hospital of Zhengzhou University, Cancer Center, Zhengzhou, China

Xudong Zhang

2 The First Affiliated Hospital of Zhengzhou University, Cancer Center, Zhengzhou, China

Jianmin Huang

1 The First Affiliated Hospital of Zhengzhou University, Biotherapy Center, Zhengzhou, China

Jia Liu

3 Gracell Biotechnologies Ltd, Shanghai, China

Gui LI

3 Gracell Biotechnologies Ltd, Shanghai, China

Jiaping He

3 Gracell Biotechnologies Ltd, Shanghai, China

Hua Zhang

3 Gracell Biotechnologies Ltd, Shanghai, China

Wei Zhao

3 Gracell Biotechnologies Ltd, Shanghai, China

Lihong Weng

3 Gracell Biotechnologies Ltd, Shanghai, China

Wenjie Yin

3 Gracell Biotechnologies Ltd, Shanghai, China

Lianjun Shen

3 Gracell Biotechnologies Ltd, Shanghai, China

Wei William Cao

3 Gracell Biotechnologies Ltd, Shanghai, China

Wenling LI

3 Gracell Biotechnologies Ltd, Shanghai, China

Mingzhi Zhang

2 The First Affiliated Hospital of Zhengzhou University, Cancer Center, Zhengzhou, China

Yi Zhang

1 The First Affiliated Hospital of Zhengzhou University, Biotherapy Center, Zhengzhou, China